1. EGFR Signaling in Liver Diseases
    Karin Komposch et al, 2015, IJMS CrossRef
  2. Multi-OMIC profiling of survival and metabolic signaling networks in cells subjected to photodynamic therapy.
    Ruud Weijer et al, 2017, Cell Mol Life Sci CrossRef
  3. A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan
    James M. Cleary et al, 2017, Invest New Drugs CrossRef
  4. ERBB4 Expression in Ovarian Serous Carcinoma Resistant to Platinum-Based Therapy
    Ozlen Saglam et al, 2017, Cancer Control CrossRef
  5. Gene copy number variation and protein overexpression of EGFR and HER2 in distal extrahepatic cholangiocarcinoma
    Min Jung Jung et al, 2017, Pathology CrossRef
  6. High-mobility group box 1 expression and lymph node metastasis in intrahepatic cholangiocarcinoma
    Yun-Fei Xu et al, 2015, WJG CrossRef
  7. The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer
    Hwajeong Lee et al, 2017, Therap Adv Gastroenterol CrossRef
  8. Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR
    Caterina Peraldo-Neia et al, 2018, PLoS ONE CrossRef
  9. Expression of epidermal growth factor receptor (EGFR) in cholangiocarcinomas: predictive factors and survival
    RODRIGO VIEIRA GOMES et al, 2018, Rev. Col. Bras. Cir. CrossRef
  10. Emerging role of precision medicine in biliary tract cancers
    James M. Bogenberger et al, 2018, npj Precision Onc CrossRef
  11. The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
    Angela Lamarca et al, 2018, PLoS ONE CrossRef
  12. The role of tumour microenvironment: a new vision for cholangiocarcinoma
    Ziyan Chen et al, 2018, J Cell Mol Med CrossRef
  13. Silencing of LAMC2 Reverses Epithelial-Mesenchymal Transition and Inhibits Angiogenesis in Cholangiocarcinoma via Inactivation of the Epidermal Growth Factor Receptor Signaling Pathway
    Yao-Fei Pei et al, 2019, The American Journal of Pathology CrossRef
  14. Rethink of EGFR in Cancer With Its Kinase Independent Function on Board
    Rintu Thomas et al, 2019, Front. Oncol. CrossRef
  15. Pertuzumab in gastrointestinal cancer
    Do-Youn Oh et al, 2016, Expert Opinion on Biological Therapy CrossRef
  16. HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
    Salvatore Galdy et al, 2017, Cancer Metastasis Rev CrossRef
  17. HER2-targeted therapies - a role beyond breast cancer.
    Do-Youn Oh et al, 2020, Nat Rev Clin Oncol CrossRef
  18. HER2 gene (ERBB2) amplification is a rare event in non-liver-fluke associated cholangiocarcinogenesis
    Thomas Albrecht et al, 2019, BMC Cancer CrossRef
  19. HER2 Overexpression as a Poor Prognostic Determinant in Resected Biliary Tract Cancer.
    Caterina Vivaldi et al, 2020, Oncologist CrossRef
  20. In vitro and in vivo Anti-Tumor Effects of Pan-HER Inhibitor Varlitinib on Cholangiocarcinoma Cell Lines


    Hasaya Dokduang et al, 2020, DDDT CrossRef
  21. Design, synthesis, biological evaluation, QSAR analysis and molecular modelling of new thiazol-benzimidazoles as EGFR inhibitors
    Aladdin M. Srour et al, 2020, Bioorganic & Medicinal Chemistry CrossRef
  22. Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
    Sakti Chakrabarti et al, 2020, Cancers CrossRef
  23. Details of HER2 status in 454 cases of biliary tract cancer
    Nobuyoshi Hiraoka et al, 2020, Human Pathology CrossRef
  24. Translating Biomarkers of Cholangiocarcinoma for Theranosis: A Systematic Review
    Imeshi Wijetunga et al, 2020, Cancers CrossRef
  25. Experimental HER2 targeted therapies for biliary tract cancer
    Alessandro Rizzo et al, 2020, Expert Opinion on Investigational Drugs CrossRef
  26. Molecular Features and Targeted Therapies in Extrahepatic Cholangiocarcinoma: Promises and Failures.
    Alessandro Rizzo et al, 2020, Cancers (Basel) CrossRef
  27. Current and New Biomarkers for Early Detection, Prognostic Stratification, and Management of Gallbladder Cancer Patients
    Patricia García et al, 2020, Cancers CrossRef
  28. JQ1 Induces DNA Damage and Apoptosis, and Inhibits Tumor Growth in a Patient-Derived Xenograft Model of Cholangiocarcinoma
    Patrick L. Garcia et al, 2018, Mol Cancer Ther CrossRef
  29. Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
    Boonyakorn Boonsri et al, 2020, Cancer Res Treat CrossRef
  30. MicroRNA-1182 and let-7a exert synergistic inhibition on invasion, migration and autophagy of cholangiocarcinoma cells through down-regulation of NUAK1
    Xin Pan et al, 2021, Cancer Cell Int CrossRef
  31. Epidermal Growth Factor Receptor Expression and Resistance Patterns to Targeted Therapy in Non-Small Cell Lung Cancer: A Review
    Emma-Anne Karlsen et al, 2021, Cells CrossRef
  32. Biomarkers in Hepatobiliary Cancers: What Is Useful in Clinical Practice?
    Alice Boilève et al, 2021, Cancers CrossRef
  33. Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR
    Yang Yang et al, 2021, Front. Cell Dev. Biol. CrossRef
  34. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
    Lauren M Lucas et al, 2022, Pharmacol Rev CrossRef
  35. Design, synthesis, and molecular modeling of quinoline‐based derivatives as anti‐breast cancer agents targeting EGFR/AKT signaling pathway
    Rasha Z. Batran et al, 2022, Chem Biol Drug Des CrossRef
  36. Systemic Therapy of Cholangiocarcinoma
    Ruben R. Plentz et al, 2016, Visc Med CrossRef
  37. Different costs of therapeutic resistance in cancer: Short- and long-term impact of population heterogeneity
    Irina Kareva, 2022, Mathematical Biosciences CrossRef
  38. Tumor Microenvironment and Immunotherapy in Advanced Biliary Tract Cancers
    Mustafa Korkmaz et al, 2022 CrossRef
  39. Evolution of Treatment in Advanced Cholangiocarcinoma: Old and New towards Precision Oncology
    Maurizio Capuozzo et al, 2022, IJMS CrossRef
  40. Postoperative Prognostic Predictors of Bile Duct Cancers: Clinical Analysis and Immunoassays of Tissue Microarrays
    Hwe Hoon Chung et al, 2023, Gut and Liver CrossRef
  41. Design, Synthesis, Anticancer Evaluation and Molecular Modeling Studies of New Thiazolidinone‐Benzoate Scaffold as EGFR Inhibitors, Cell Cycle Interruption and Apoptosis Inducers in HepG2
    Salwa Magdy Eldaly et al, 2023, Chemistry & Biodiversity CrossRef
  42. ErBb Family Proteins in Cholangiocarcinoma and Clinical Implications
    Wook Jin, 2020, JCM CrossRef
  43. HER2 amplification subtype intrahepatic cholangiocarcinoma exhibits high mutation burden and T cell exhaustion microenvironment
    Xiaohong Pu et al, 2024, J Cancer Res Clin Oncol CrossRef
  44. Cholangiocyte ciliary defects induce sustained epidermal growth factor receptor signaling
    Kishor Pant et al, 2024 CrossRef